Hinge Health's New FDA-Cleared Migraine Device: Everything You Need to Know

Hinge Health, widely recognized for its digital musculoskeletal (MSK) care platform, is making a bold leap into neurology with a newly FDA-cleared device designed to treat migraines. This move signals a strategic expansion beyond joint and back pain into a condition affecting over 1 billion people worldwide. In this Q&A, we break down what the device does, how it works, and what it means for patients and digital health.

What exactly is Hinge Health's new FDA-cleared device for migraines?

The device is a wearable, non-invasive neuromodulation system that delivers electrical stimulation to specific nerves to prevent or treat migraine attacks. It has received 510(k) clearance from the FDA, meaning it is substantially equivalent to an existing legally marketed device. Hinge Health, known for its digital therapy programs, will integrate this device into a broader digital care pathway that includes behavioral coaching and medication management. The goal is to offer a drug-free, at-home option for migraine sufferers who may not respond well to or tolerate traditional medications.

How does the device work to relieve migraines?

The device uses transcutaneous electrical nerve stimulation (TENS) or a similar neuromodulation mechanism to target nerves implicated in migraine pathophysiology, such as the trigeminal nerve or occipital nerves. By applying mild electrical pulses through electrodes placed on the skin, it modulates pain signaling pathways and may reduce the frequency and intensity of migraine attacks. Users typically wear it for a set period each day—either for prevention at the first sign of an aura or during an acute episode. Clinical studies supporting FDA clearance showed a statistically significant reduction in migraine days compared to a sham control, with minimal side effects like mild skin irritation.

Who is eligible to use this migraine device?

The device is intended for adults with episodic or chronic migraine, as defined by the International Classification of Headache Disorders. It is not recommended for individuals with implanted electrical devices (e.g., pacemakers), those who are pregnant, or those with certain skin conditions at the electrode placement site. Hinge Health plans to offer the device as part of a comprehensive digital program, so users will likely undergo a clinical assessment via their platform to determine candidacy. As an FDA-cleared device, it can be prescribed by healthcare providers or obtained through Hinge Health's direct-to-consumer pathway, depending on regional regulations.

How does this compare to other FDA-cleared migraine devices like Nerivio or Cefaly?

Like Nerivio (a smartphone-controlled armband) and Cefaly (a forehead stimulator), Hinge Health's device is non-invasive and prescription-free in some cases. However, Hinge Health differentiates itself by bundling the hardware with its existing digital therapeutics ecosystem. Users get access to physical therapy–inspired exercises (adapted for migraine), cognitive behavioral therapy for pain management, and medication tracking—all via a single app. This holistic approach may improve adherence and outcomes compared to standalone devices. Additionally, Hinge Health's device targets a different nerve pathway than some competitors, potentially offering an alternative for patients who did not respond to other neuromodulation devices.

Why is Hinge Health, a company focused on MSK, entering the migraine space?

Migraines and musculoskeletal pain often co-occur, with studies showing that up to 75% of migraine sufferers also experience neck or back pain. Hinge Health sees an opportunity to leverage its established digital platform—which uses sensors, AI, and coaching—to address this comorbidity. By adding a migraine device to its portfolio, the company can offer a unified care pathway for overlapping pain conditions. Financially, the move diversifies its revenue beyond employer contracts for MSK care into the larger migraine treatment market, which was valued at over $10 billion in 2023. It also aligns with the growing trend of digital health companies expanding into adjacent chronic conditions.

What does FDA clearance mean for patients, and are there any risks?

FDA 510(k) clearance indicates that the device is as safe and effective as a legally marketed predicate device, but it does not mean the device has undergone the rigorous clinical trials required for a novel drug. Patients should expect mild risks like skin redness or discomfort at electrode sites, but serious adverse events are rare. The clearance also paves the way for insurance coverage in some cases, though not guaranteed. Hinge Health will need to generate real-world evidence to convince payers. For now, the device is available through Hinge Health's direct channels and may be reimbursable under flexible spending accounts (FSAs) or health savings accounts (HSAs).

How can I try or get prescribed Hinge Health's migraine device?

As of the announcement, Hinge Health is rolling out the device gradually, starting with existing users of its MSK program who also report migraines. Eventually, it will be available as a standalone offering through Hinge Health's app or website. You may need to complete an online assessment or consult with a Hinge Health clinician to confirm eligibility. The company also partners with employers and health plans to offer the device as a covered benefit. For those interested, checking Hinge Health's official site or contacting customer support is the best first step. Always consult with your healthcare provider before starting any new migraine treatment.

This article was updated based on original reporting from STAT's Health Tech newsletter.